Expertise in
31
conditions

Dr. Jesus G. Berdeja

Oncology
250 25th Ave N, Ste 412, 
Nashville, TN 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
27 Years of Experience
Expertise in
31
conditions
250 25th Ave N, Ste 412, 
Nashville, TN 

Overview

Jesus Berdeja is an Oncologist practicing medicine in Nashville, Tennessee. He has been practicing medicine for over 27 years.

Dr. Berdeja is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Acute Myeloid Leukemia (AML), and Bone Marrow Aspiration.

Dr. Berdeja is board certified in The American Board Of Internal Medicine - Hematology. He is actively involved in clinical research, co-authoring 121 peer reviewed articles and participating in 13 clinical trials. Dr. Berdeja is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in TN

Board Certifications

The American Board Of Internal Medicine - Hematology

Fellowships

Johns Hopkins

Hospital Affiliations

Tristar Centennial Medical Center
Ascension Saint Thomas Hospital
Ascension Saint Thomas Hospital Midtown

Languages Spoken

English
French
Russian
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
US Health and Life
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Tennessee Oncology, PLLC-#412 25th Ave
250 25th Ave N, Ste 412, Nashville, TN 37203

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma
Enrollment Status: Recruiting
Publish Date: July 15, 2026
Intervention Type: Drug
Study Drugs: Selinexor, Dexamethasone, Lenalidomide, Pomalidomide, Bortezomib, Daratumumab, Carfilzomib, Ixazomib, Elotuzumab, Clarithromycin, Belantamab Mafodotin
Study Phase: Phase 1/Phase 2
A Multicenter, Open-Label, Single Arm, Phase II Study of Daratumumab as Consolidation/Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Multiple Myeloma
A Multicenter, Open-Label, Single Arm, Phase II Study of Daratumumab as Consolidation/Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: August 05, 2026
Intervention Type: Biological, Drug, Other, Procedure
Study Drugs: Daratumumab, Melphalan
Study Phase: Phase 2
A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 8)
A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 8)
Enrollment Status: Active_not_recruiting
Publish Date: June 12, 2026
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Pomalidomide, Dexamethasone, Bortezomib
Study Phase: Phase 3
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
Enrollment Status: Completed
Publish Date: April 03, 2026
Intervention Type: Drug
Study Drug: ASTX727
Study Phase: Phase 1/Phase 2
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: November 10, 2025
Intervention Type: Drug, Biological
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 2
Phase 2 Study of Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Phase 2 Study of Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Enrollment Status: Terminated
Publish Date: October 08, 2024
Intervention Type: Biological
Study Drug: Descartes 08
Study Phase: Phase 2
A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET (Bromodomain and Extra-terminal) Proteins, in Patients With Previously Treated Multiple Myeloma
A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET (Bromodomain and Extra-terminal) Proteins, in Patients With Previously Treated Multiple Myeloma
Enrollment Status: Completed
Publish Date: April 18, 2024
Intervention Type: Drug
Study Phase: Phase 1
Phase 2 Trial of Pomalidomide, Ixazomib and Dexamethasone in Patients With Multiple Myeloma With Extramedullary Disease or Plasma Cell Leukemia
Phase 2 Trial of Pomalidomide, Ixazomib and Dexamethasone in Patients With Multiple Myeloma With Extramedullary Disease or Plasma Cell Leukemia
Enrollment Status: Completed
Publish Date: October 30, 2023
Intervention Type: Drug, Other
Study Drugs: Dexamethasone, Ixazomib Citrate, Pomalidomide
Study Phase: Phase 2
A Phase I Open Label First in Human Dose Escalation of the Immunoproteasome Inhibitor M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone in Participants With Relapsed Refractory Multiple Myeloma
A Phase I Open Label First in Human Dose Escalation of the Immunoproteasome Inhibitor M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone in Participants With Relapsed Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: March 24, 2023
Intervention Type: Drug
Study Drugs: M3258, Dexamethasone
Study Phase: Phase 1
A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK 001) in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting.
A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK 001) in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting.
Enrollment Status: Unknown
Publish Date: February 16, 2023
Intervention Type: Biological
Study Drug: CYNK-001
Study Phase: Phase 1
View 9 Less Clinical Trials

121 Total Publications

Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.
Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.
Journal: Blood cancer journal
Published: August 31, 2026
Similar Doctors
Expertise in
39
conditions
Expertise in
39
conditions
Referral may be required

Tennessee Oncology, PLLC-#412 25th Ave

250 25th Ave N, Ste 412, 
Nashville, TN 
 (0.1 miles away)
615-986-7600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ian Flinn is an Oncologist practicing medicine in Nashville, Tennessee. Dr. Flinn is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Non-Hodgkin Lymphoma, and Bone Marrow Aspiration. Dr. Flinn is board certified in The American Board Of Internal Medicine - Hematology. Dr. Flinn is currently accepting new patients.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

SCRI Oncology Partners

335 24th Ave N, Ste 200, 
Nashville, TN 
 (1.2 miles away)
615-329-7640
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Erika Hamilton, MD, is an independent medical oncologist and hematologist at Ascension Saint Thomas in Nashville, Tennessee. Dr. Hamilton diagnoses and treats adults with cancer and focuses on managing care during and after chemotherapy, radiation therapy and surgery. Every appointment with Dr. Hamilton starts with a conversation. She takes the time to answer all your questions — big and small. Dr. Hamilton is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, HER2 Negative Breast Cancer, Ovarian Cancer, and HER-2 Positive Breast Cancer. Dr. Hamilton is board certified in The American Board Of Internal Medicine - Medical Oncology. Dr. Hamilton is currently accepting new patients.

Expertise in
29
conditions
Expertise in
29
conditions
Referral may be required

SCRI Oncology Partners

335 24th Ave N, Ste 200, 
Nashville, TN 
 (1.2 miles away)
615-329-7640
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Spigel is an Oncologist practicing medicine in Nashville, Tennessee. Dr. Spigel is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma. Dr. Spigel is board certified in The American Board Of Internal Medicine - Medical Oncology. Dr. Spigel is currently accepting new patients.

Frequently Asked Questions about Dr. Jesus G. Berdeja

How do I make an appointment with Dr. Jesus G. Berdeja?

You can book an appointment with Dr. Jesus G. Berdeja by calling their office at 615-986-7600. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jesus G. Berdeja a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jesus G. Berdeja is classified as an Elite expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jesus G. Berdeja specialize in?

While Dr. Jesus G. Berdeja is a Oncology, they have specific expertise in Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), and Smoldering Multiple Myeloma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Jesus G. Berdeja participate in research or clinical trials?

Yes. Dr. Jesus G. Berdeja has published 121 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Jesus G. Berdeja's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jesus G. Berdeja accept my insurance?

Dr. Jesus G. Berdeja accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 615-986-7600 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Berdeja's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 21 Advanced Conditions
View All 21 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile